Clinical Trials Insight: 700036263
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2009
At a glance
- Drugs CX 1739 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors RespireRx Pharmaceuticals
- 28 Jan 2009 Status changed from planning to not yet recruiting, according to a Cortex Pharmaceuticals media release.
- 15 Aug 2008 New trial record.